Hut 8 shares jumped 15.2% to $21.28 on Wednesday. Here are some other big stocks recording gains in today’s session. Blue Gold Limited BGL gained 56.88% to $112.84 after jumping 74% on Tuesday.

Sionna’s NBD1 stabilizers, SION-719 and SION-451, showed high-affinity binding and increased stability of the defective protein. When combined with either SION-2222 or SION-109, the company’s ...

Sionna Therapeutics, Inc. has announced the presentation of promising preclinical data at the 48th European Cystic Fibrosis Conference in Milan, showing that its nucleotide-binding domain 1 (NBD1 ...

Sionna's goal is to deliver differentiated medicines for people living with CF that can restore their CFTR function to as close to normal as possible by directly stabilizing CFTR's nucleotide ...

Sionna plans to advance SION-719 into a Phase 2a proof-of-concept trial, with the U.S. FDA having cleared the Investigational New Drug application.

Sionna has completed Phase 1 clinical trials evaluating two potent first-in-class small molecule NBD1 stabilizers, SION-719 and SION-451. The company is also developing modulators with mechanisms of ...

WALTHAM, Mass., June 06, 2025 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm ...

Sionna has completed Phase 1 clinical trials evaluating two potent first-in-class small molecule NBD1 stabilizers, SION-719 and SION-451. The company is also developing modulators with mechanisms of ...

Sionna plans to advance SION-719 to a Phase 2a proof-of-concept add-on to standard of care trial in cystic fibrosis patients, and SION-451 to a Phase 1 healthy volunteer dual combination trial Next ...